AstraZeneca and Daiichi Report Results of Trastuzumab Deruxtecan (DS-8201) in P-II DESTINY-Breast01 Study for Refractory HER2+ Metastatic Breast Cancer

AstraZeneca and Daiichi Report Results of Trastuzumab Deruxtecan (DS-8201) in P-II DESTINY-Breast01 Study for Refractory HER2+ Metastatic Breast Cancer

Shots:

  • The P-II DESTINY-Breast01 study involves assessing of Trastuzumab Deruxtecan (DS-8201) in 253 patients with HER2+ unresectable and/or m-breast cancer prior treated with trastuzumab emtansine
  • The P-II DESTINY-Breast01 study result: met its 1EPs; safe & tolerable as in previous trials; supporting the onset of FDA’s BLA submission in H2’19
  • Trastuzumab Deruxtecan (DS-8201) is an ADC, delivers cytotoxic agents to the targeted cancer cell via linker attached to a mAb, currently evaluating in 5 trials for multiple cancer and has received FDA’s BT & MHLW’s Sakigake designation for HER2+ LA/m-breast cancer & adnavced gastric cancer respectively

Click here to read full press release/ article | Ref: AstraZeneca | Image: Glassdoor